PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21871559-5 2011 Low tert-butylhydroperoxide (tBH) concentrations similarly mediated promoter activation, but the maximal activation dose was decreased 10-fold by insulin. tert-Butylhydroperoxide 4-27 insulin Homo sapiens 146-153 21871559-5 2011 Low tert-butylhydroperoxide (tBH) concentrations similarly mediated promoter activation, but the maximal activation dose was decreased 10-fold by insulin. tert-Butylhydroperoxide 29-32 insulin Homo sapiens 146-153 21871559-6 2011 Insulin-tBH coadministration abrogated the low or high glucose requirement for promoter activation, suggesting possible ROS involvement. tert-Butylhydroperoxide 8-11 insulin Homo sapiens 0-7 18926903-4 2008 However, on tert-butylhydroperoxide challenge, insulin-treated cells demonstrated a robust GSH recovery that was attributed to a greater capacity for de novo synthesis via elevated GCLc levels. tert-Butylhydroperoxide 12-35 insulin Homo sapiens 47-54 7533613-16 1995 The intracellular "hydroperoxide donor" tert-butylhydroperoxide in the concentration range of 0.03-3 mM inhibited insulin release stimulated by the nutrient secretagogues glucose and L-arginine. tert-Butylhydroperoxide 40-63 insulin Homo sapiens 114-121 7533613-24 1995 The mechanism underlying the secretion promoting action of tert-butylhydroperoxide on IBMX-induced insulin release is probably linked to intracellular Ca2+-perturbations affecting exocytosis.8. tert-Butylhydroperoxide 59-82 insulin Homo sapiens 99-106 4460-7 1976 Tert-butyl hydroperoxide (2 X 10(-3) M), a glutathione-oxidizing reagent, inhibited degradation by 35 to 50%, possibly due to an effect on a glutathione-insulin transhydrogenase. tert-Butylhydroperoxide 0-24 insulin Homo sapiens 153-160